The Randomized Trial on the Clinical Management of ASCUS and LSIL of the Uterine cervix is designed to: l) Determine whether human papillomavirus(HPV) testing can effectively triage women with a cytologic diagnosis of ASCUS (atypical squamous cells of undetermined significance) or LSIL (low-grade squamous intraepithelial lesion) 2) Develop clinical management guidelines and provide prognostic information for the ASCUS and LSIL diagnostic categories of the Bethesda System, and 3) Determine whether the cost of screening and treatment for the potential precursor lesions of cervical cancer can be reduced though improved triage. The Contractor shall establish a Study Coordinating and Data Management Unit (CU) for the Trial to develop and maintain systems and procedures needed for biomedical data management, study coordination, statistical analysis and report writing. The CU in its coordination efforts shall act as a liaison between the Clinical Centers, the Quality Control Groups, study consultants, and the National Cancer Institute Project Officers.

National Institute of Health (NIH)
Division of Cancer Prevention And Control (NCI)
Research and Development Contracts (N01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Westat, Inc.
United States
Zip Code
Wilson, Lauren; Pawlita, Michael; Castle, Phillip E et al. (2014) Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis 210:448-55
Gage, Julia C; Schiffman, Mark; Solomon, Diane et al. (2013) Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities. Cancer Epidemiol Biomarkers Prev 22:1095-101
Wilson, Lauren E; Pawlita, Michael; Castle, Phillip E et al. (2013) Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study. Int J Cancer 133:2172-81
Marks, Morgan A; Castle, Philip E; Schiffman, Mark et al. (2012) Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol 50:300-6
Castle, Philip E; Gravitt, Patti E; Wentzensen, Nicolas et al. (2012) A descriptive analysis of prevalent vs incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am J Clin Pathol 138:241-6
Campos, Nicole G; Castle, Philip E; Schiffman, Mark et al. (2012) Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study. Med Decis Making 32:400-27
Castle, Philip E; Gage, Julia C; Wheeler, Cosette M et al. (2011) The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol 118:1222-9
Castle, Philip E; Gutierrez, Erin C; Leitch, Sharon V et al. (2011) Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol 49:3029-32
Gage, Julia C; Schiffman, Mark; Solomon, Diane et al. (2010) Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev 19:1668-74
Castle, Philip E; Schiffman, Mark; Wheeler, Cosette M et al. (2010) Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 171:155-63

Showing the most recent 10 out of 18 publications